Impact of the withdrawal of the UK from the EU on the availability of medicinal products in Cyprus
The Pharmaceutical Services of the Ministry of Health detected early the medicinal products at risk of been affected by the withdrawal of the UK from the EU and addressed the issue with the Marketing Authorisation Holders who are responsible for the marketing of the medicinal products in order for them to take the necessary actions so the continuation of their products in the Cyprus market is maintained.
The transition period until the end of 2020 as provided for in the UK Withdrawal Agreement, is expected to provide additional time to all affected stakeholders to take all necessary actions for regulatory compliance in accordance with the withdrawal agreement.
The Pharmaceutical Services are in continuous communication with the stakeholders and the European Commission and closely monitor the developments so they will be able to respond to the challenges that may present, with a view to minimize the impact of the withdrawal of the UK on the availability of medicines.
On 31 January 2020, the United Kingdom withdrew from the European Union. At the same time, from 1 February 2020, the transitional period, which will last until 31 December 2020, begins and will maintain the existing situation for citizens and businesses.
During this transitional period medical devices whose Manufacturer and/or Notified Body is based in the United Kingdom may continue to be placed on the Cyprus Market.
However, since the economic operators involved had been properly prepared for the possibility of a hard Brexit, it is not expected that there will be any problems with products that already placed on the Cyprus market.
For more information you can visit the website of the Ministry of Health at the following link: https://www.moh.gov.cy/moh/moh.nsf/All/C80393B1BA184FCDC22583BE003D8BD0